Advance Search
Volume 30 Issue 9
Sep.  2014
Turn off MathJax
Article Contents

doi: 10.11847/zgggws2014-30-09-37
  • Received Date: 2014-03-10
  • Publish Date: 2014-09-10
  • loading
  • [1]
    World Health Organization.Global tuberculosis control 2011[R].Geneva:World Health Organization,2011.
    [2]
    World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis[R].Geneva:World Health Organization,2008.
    [3]
    Frieden TR,Sterling TR,Munsiff SS,et al.Tuberculosis[J].Lancet,2003,362(9387):887-899.
    [4]
    Frieden TR,Sterling T,Pablos-Mendez A,et al.The emergence of drug-resistant tuberculosis in New York City[J].N Engl J Med,1993,328(8):521-526.
    [5]
    Pablos-Mendez A,Raviglione MC,Laszlo A,et al.Global surveillance for antituberculosis-drug resistance,1994-1997.World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on anti-tuberculosis drug resistance surveillance[J].N Engl J Med,1998,338(23):1641-1649.
    [6]
    Espinal MA,Laszlo A,Simonsen L,et al.Global trends in resistance to antituberculosis drugs.World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-tuberculosis Drug Resistance Surveillance[J].N Engl J Med,2001,344(17):1294-1303.
    [7]
    Gandhi NR,Moll A,Sturm AW,et al.Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of south africa[J].Lancet,2006,368(9547):1575-1580.
    [8]
    World Health Organization.Multidrug and extensively drug-resistant Tb(M/Xdr-Tb):2010 global report on surveillance and response[R].Geneva:World Health Organization,2010.
    [9]
    Shah NS,Wright A,Bai GH,et al.Worldwide emergence of extensively drug-resistant tuberculosis[J].Emerg Infect Dis,2007,13(3):380-387.
    [10]
    Gandhi NR,Nunn P,Dheda K,et al.Multidrug-resistant and extensively drug-resistant tuberculosis:a threat to global control of tuberculosis[J].Lancet,2010,375(9728):1830-1843.
    [11]
    World Health Organization.Anti-tuberculosis drug resistance in the world:report 4[R].Geneva:World Health Organization,2008.
    [12]
    Bloss E,Kuksa L,Holtz TH,et al.Adverse events related to multidrug-resistant tuberculosis treatment,Latvia,2000-2004[J].Int J Tuberc Lung Dis,2010,14(3):275-281.
    [13]
    Nathanson E,Gupta R,Huamani P,et al.Adverse events in the treatment of multidrug-resistant tuberculosis:results from the dots-plus initiative[J].Int J Tuberc Lung Dis,2004,8(11):1382-1384.
    [14]
    Inge LD,Wilson JW.Update on the treatment of tuberculosis[J].Am Fam Physician,2008,78(4):457-465.
    [15]
    Ormerod LP.Multidrug-resistant tuberculosis(Mdr-Tb):epidemiology,prevention and treatment[J].Br Med Bull,2005,73-74:17-24.
    [16]
    World Health Organization.Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015[R].Geneva:World Health Organization,2011.
    [17]
    Pablos-Mendez A,Raviglione MC,Laszlo A,et al.Global surveillance for antituberculosis-drug resistance,1994-1997.World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on anti-tuberculosis drug resistance surveillance[J].N Engl J Med,1998,338(23):1641-1649.
    [18]
    Wright A,Zignol M,Van Deun A,et al.Epidemiology of antituberculosis drug resistance 2002-07:an updated analysis of the global project on anti-tuberculosis drug resistance surveillance[J].Lancet,2009,373(9678):1861-1873.
    [19]
    Zignol M,van Gemert W,Falzon D,et al.Surveillance of anti-tuberculosis drug resistance in the world:an updated analysis,2007-2010[J].Bull World Health Organ,2012,90(2):111-119.
    [20]
    He GX,Zhao YL,Jiang GL,et al.Prevalence of tuberculosis drug resistance in 10 provinces of China[J].BMC Infect Dis,2008,8:166.
    [21]
    王国斌,彭义利,张国龙,等.河南省WHO结核病耐药监测报告[J].中国防痨杂志,1999,21(3):60-61.
    [22]
    杜长梅,王国斌,徐吉英,等.河南省第二轮结核病耐药监测及耐药趋势研究[J].中国防痨杂志,2006,28(2):95-100.
    [23]
    王甦民,刘宇红,姜广路,等.世界卫生组织中国结核病耐药监测的结果评价[J].中华检验医学杂志,2007,30(8):863-866.
    [24]
    刘洁,靖宽和,刘英,等.2005年重庆市结核病耐药监测结果分析[J].检验医学与临床,2009,6(12):963-965.
    [25]
    王甦民,张福生,端木宏谨.山东省耐药结核病流行状况研究[J].中华结核和呼吸杂志,1999,22(12):23-25.
    [26]
    李群,王晓萌,何海波,等.WHO 浙江省结核病耐药监测研究报告[J].中华结核和呼吸杂志,2000,23(12):718-721.
    [27]
    钟球,钱明,李建伟,等.广东省 WHO 结核病耐药监测研究[J].中国防痨杂志,2001,23(1):6-9.
    [28]
    李国明,吴兴荣,张缇,等.湖北省结核分支杆菌耐药性监测研究[J].中华结核和呼吸杂志,2002,25(12):22-25.
    [29]
    谢艳光,李发斌,闫兴录.黑龙江省 WHO 结核病耐药监测报告[J].中国防痨杂志,2008,30(5):395-398.
    [30]
    安燕生,丁北川,朱建华,等.北京市 WHO 结核病药物耐药性监测研究[J].中国防痨杂志,2007,29(6):475-478.
    [31]
    梅建,沈鑫,沈梅,等.上海市结核分枝杆菌耐药性监测研究报告[J].中国防痨杂志,2007,29(5):395-398.
    [32]
    贾卫,吴卫东,张伟,等.WHO 新疆结核病耐药监测报告[J].中国防痨杂志,2008,30(4):307-310.
    [33]
    司红艳,李晴,穆洮俊,等.甘肃省临夏州、甘南州、定西市结核病耐药监测结果分析[J].中国防痨杂志,2009,31(4):206-209.
    [34]
    钟球,尹建军,钱明,等.广东省结核病耐药性基线调查研究[J].中国防痨杂志,2011,33(7):393-399.
    [35]
    陈松华,王晓萌,柳正卫,等.浙江省耐多药结核病例中二线耐药状况分析[J].中国预防医学杂志,2011,12(9):761-764.
    [36]
    黄曙海,蓝如束,刘飞鹰,等.广西壮族自治区肺结核耐药性调查及复治患者耐药相关因素分析[J].中国防痨杂志,2013,35(9):711-717.
    [37]
    中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007-2008)[R].北京:人民卫生出版社,2009:130.
    [38]
    陈军.武汉地区结核分枝杆菌药物敏感性及氟喹诺酮耐药分子机制的研究[D].武汉:华中科技大学博士学位论文,2011.
    [39]
    Espinal MA,Laserson K,Camacho M,et al.Determinants of drug-resistant tuberculosis:analysis of 11 countries[J].Int J Tuberc Lung Dis,2001,5(10):887-893.
    [40]
    王黎霞.中国结核病防治工作现状分析[J].中国公共卫生,2012,28(4):413-414.
    [41]
    Faustini A,Hall AJ,Perucci CA.Risk factors for multidrug resistant tuberculosis in europe:a systematic review[J].Thorax,2006,61(2):158-163.
    [42]
    Zhao Y,Xu S,Wang L,et al.National survey of drug-resistant tuberculosis in China[J].N Engl J Med,2012,366(23):2161-2170.
    [43]
    Shen X,DeRiemer K,Yuan ZA,et al.Drug-resistant tuberculosis in shanghai,China,2000-2006:prevalence,trends and risk factors[J].Int J Tuberc Lung Dis,2009,13(2):253-259.
    [44]
    Caminero JA.Likelihood of generating Mdr-Tb and Xdr-Tb under adequate national tuberculosis control programme implementation[J].Int J Tuberc Lung Dis,2008,12(8):869-877.
    [45]
    周丽莎,耿文奎.结核病耐药原因分析[J].中国公共卫生,2009,29(5):524-526.
    [46]
    Nic FC,Vargas-Prada S,Huancare V,et al.Physician-initiated courtesy mods testing for Tb and Mdr-Tb diagnosis and patient management[J].Int J Tuberc Lung Dis,2008,12(5):555-560.
    [47]
    Zhao M,Li X,Xu P,et al.Transmission of Mdr and Xdr tuberculosis in Shanghai,China[J].PLoS One,2009,4(2):e4370.
    [48]
    Liang L,Wu Q,Gao L,et al.Factors contributing to the high prevalence of multidrug-resistant tuberculosis:a study from China[J].Thorax,2012,67(7):632-638.
    [49]
    Lomtadze N,Aspindzelashvili R,Janjgava M,et al.Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia:a population-based study[J].Int J Tuberc Lung Dis,2009,13(1):68-73.
    [50]
    Law WS,Yew WW,Chiu LC,et al.Risk factors for multidrug-resistant tuberculosis in Hong Kong[J].Int J Tuberc Lung Dis,2008,12(9):1065-1070.
    [51]
    Gilad J,Borer A,Riesenberg K,et al.Epidemiology and ethnic distribution of multidrug-resistant tuberculosis in Southern Israel,1992-1997:the impact of immigration[J].Chest,2000,117(3):738-743.
    [52]
    Suarez-Garcia I,Rodriguez-Blanco A,Vidal-Perez JL,et al.Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid,Spain[J].Eur J Clin Microbiol Infect Dis,2009,28(4):325-330.
    [53]
    Heym B,Honore N,Truffot-Pernot C,et al.Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis:a molecular study[J].Lancet,1994,344(8918):293-298.
    [54]
    Ano H,Matsumoto T,Suetake T,et al.Relationship between the isoniazid-resistant mutation katgs315T and the prevalence of Mdr-/Xdr-Tb in Osaka,Japan[J].Int J Tuberc Lung Dis,2008,12(11):1300-1305.
    [55]
    胡屹.中国华东农村地区耐药结核病流行和传播的分子流行病学研究[D].上海:复旦大学博士学位论文,2008.
    [56]
    Lewis K.Persister Cells,Dormancy and infectious disease[J].Nat Rev Microbiol,2007,5(1):48-56.
    [57]
    Cohen T,Sommers B,Murray M.The effect of drug resistance on the fitness of Mycobacterium tuberculosis[J].Lancet Infect Dis,2003,3(1):13-21.
    [58]
    Caminero JA.Multidrug-resistant tuberculosis:epidemiology,risk factors and case finding[J].Int J Tuberc Lung Dis,2010,14(4):382-390.
    [59]
    Aguilar D,Hanekom M,Mata D,et al.Mycobacterium tuberculosis strains with the Beijing genotype demonstrate variability in virulence associated with transmission[J].Tuberculosis(Edinb),2010,90(5):319-325.
    [60]
    Lasunskaia E,Ribeiro SC,Manicheva O,et al.Emerging multidrug resistant Mycobacterium tuberculosis strains of the Beijing genotype circulating in russia express a pattern of biological properties associated with enhanced virulence[J].Microbes Infect,2010,12(6):467-475.
    [61]
    de Steenwinkel JE,Ten KM,de Knegt GJ,et al.Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with Mdr Tb[J].Emerg Infect Dis,2012,18(4):660-663.
    [62]
    Spradling P,Nemtsova E,Aptekar T,et al.Anti-tuberculosis drug resistance in community and prison patients,Orel Oblast,Russian Federation[J].Int J Tuberc Lung Dis,2002,6(9):757-762.
    [63]
    Teixeira L,Perkins MD,Johnson JL,et al.Infection and disease among household contacts of patients with multidrug-resistant tuberculosis[J].Int J Tuberc Lung Dis,2001,5(4):321-328.
    [64]
    Tanrikulu AC,Abakay A,Abakay O.Risk factors for multidrug-resistant tuberculosis in diyarbakir,turkey[J].Med Sci Monit,2010,16(6):H57-62.
    [65]
    Granich RM,Oh P,Lewis B,et al.Multidrug resistance among persons with tuberculosis in california,1994-2003[J].JAMA,2005,293(22):2732-2739.
    [66]
    Casal M,Vaquero M,Rinder H,et al.A case-control study for multidrug-resistant tuberculosis:risk factors in four european countries[J].Microb Drug Resist,2005,11(1):62-67.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Article views (657) PDF downloads(65) Cited by()
    Proportional views

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return